BioPharmSignal logoBioPharmSignal

Biotech News

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

Vaxcyte (PCVX)VaxcyteConference / presentation

SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15

Related news

PCVXVaxcyte2026-10-04 21:00 EST

Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

PCVXVaxcyte2026-10-05 10:00 EST

Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

VXRTVaxart2026-02-18 13:00 EST

Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026

VXRTVaxart2026-09-08 12:00 EST

Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GSKGSK plc2026-01-07 12:00 EST

GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved by the European Commission

GSKGSK plc2025-10-21 07:05 EST

GSK’s Shingrix new prefilled syringe presentation receives positive CHMP opinion

View all latest news

Vaxcyte

Carrier-Sparing Vaccine Platform Vaxcyte develops broad-spectrum conjugate vaccines using a platform designed to include more bacterial antigens without overloading the carrier proteins needed to generate immune responses. Adult VAX-31 Program VAX-31 is a 31-valent pneumococcal conjugate vaccine in Phase 3 development for adults. The...

Recent company news

PCVXVaxcyte2026-10-07 02:49 EST

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

PCVXVaxcyte2026-10-05 20:28 EST

Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

PCVXVaxcyte2026-10-05 10:00 EST

Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

PCVXVaxcyte2026-10-04 21:00 EST

Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

PCVXVaxcyte2026-09-03 20:05 EST

Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data

Stock data

Close
66.70 USD
Market cap
6.85B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States